Clinical Trial Update: Safety of HMA-CD20 in Patients With HFrEF [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing safety of HMA-CD20 in patients with heart failure with reduced ejection fraction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• HMA-CD20

Snippet

Sponsor: Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud | Conditions: Heart Failure With Reduced Ejection Fraction | Phase 2 | Status: UNKNOWN